Infinity Pharmaceuticals Inc. (INFI) Expected to Announce Earnings of -$0.16 Per Share

Equities research analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.16) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Infinity Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.14). Infinity Pharmaceuticals posted earnings per share of ($0.12) in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The business is expected to issue its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.73) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.71). For the next financial year, analysts anticipate that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.54). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.19). The firm had revenue of $2.14 million for the quarter, compared to analyst estimates of $10.07 million.

A number of brokerages have recently commented on INFI. ValuEngine downgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 26th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. Infinity Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $2.50.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in shares of Infinity Pharmaceuticals by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,101,085 shares of the biotechnology company’s stock worth $1,299,000 after buying an additional 35,211 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Infinity Pharmaceuticals by 8.4% during the first quarter. Renaissance Technologies LLC now owns 891,200 shares of the biotechnology company’s stock worth $1,675,000 after buying an additional 69,300 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Infinity Pharmaceuticals by 12.5% during the first quarter. Acadian Asset Management LLC now owns 542,519 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 60,383 shares in the last quarter. Fosun International Ltd grew its holdings in shares of Infinity Pharmaceuticals by 10.6% during the first quarter. Fosun International Ltd now owns 418,296 shares of the biotechnology company’s stock worth $786,000 after buying an additional 40,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Infinity Pharmaceuticals by 48.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 191,927 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 62,800 shares during the period. Institutional investors and hedge funds own 54.33% of the company’s stock.

Shares of NASDAQ INFI traded up $0.05 during midday trading on Friday, reaching $1.64. 714 shares of the stock were exchanged, compared to its average volume of 94,132. The company has a market cap of $93.93 million, a PE ratio of -8.25 and a beta of 1.95. Infinity Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $2.92.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Read More: How to invest in blue-chip stocks

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.